Safety and immunogenicity after a 30month boost of a subtype C ALVACHIV vCP2438 vaccine prime plus bivalent subtype C gp120 MF59 vaccine boost HVTN 100 A phase 12 randomized doubleblind placebocontrolled trial

Vimla NaickerFatima LaherL BekkerK SeatonM AllenE et alLynn MorrisNonhlanhla Mkhize2025-03-29DOAJhttps://hdl.handle.net/10539/44505Safety and immunogenicity after a 30month boost of a subtype C ALVACHIV vCP2438 vaccine prime plus bivalent subtype C gp120 MF59 vaccine boost HVTN 100 A phase 12 randomized doubleblind placebocontrolled trialJournal Article